Setting the “right” goal: post M&A innovation performance and goal orientation

Pharmaceutical firms spend billions of dollars to develop the next breakthrough drug and to maintain their market shares. We investigate how pharmaceutical firms use mergers and acquisitions to boost their innovation performance which has been found to result in better performance outcomes. Adding...

Full description

Bibliographic Details
Main Author: Trang Thu Doan
Format: Article
Language:English
Published: Vilnius Gediminas Technical University 2020-09-01
Series:Business: Theory and Practice
Subjects:
R&D
Online Access:https://journals.vgtu.lt/index.php/BTP/article/view/12083
id doaj-bb99d82790044782958fbfbc8dbd3396
record_format Article
spelling doaj-bb99d82790044782958fbfbc8dbd33962020-11-25T03:31:03ZengVilnius Gediminas Technical UniversityBusiness: Theory and Practice1648-06271822-42022020-09-0121210.3846/btp.2020.12083Setting the “right” goal: post M&A innovation performance and goal orientationTrang Thu Doan0International School, Vietnam National University Hanoi, Vietnam Pharmaceutical firms spend billions of dollars to develop the next breakthrough drug and to maintain their market shares. We investigate how pharmaceutical firms use mergers and acquisitions to boost their innovation performance which has been found to result in better performance outcomes. Adding to the recent research on mergers and acquisitions, we found that firms that are explicit with their R&D goal orientation from the beginning of the acquisition journey are more successful in their innovation endeavours than firms with other goal orientation. Further, the firms’ prior acquisition experience appears to aid their innovation performance. However, we found that target size can affect the post-acquisition innovation performance but has diminishing returns as target size increases. Ultimately, our findings suggest that having an explicit R&D goal orientation is really important for a healthy innovation pipeline for pharmaceutical firms. https://journals.vgtu.lt/index.php/BTP/article/view/12083mergers and acquisitionsinnovationR&Dgoal orientationacquisition experienceorganizational learning
collection DOAJ
language English
format Article
sources DOAJ
author Trang Thu Doan
spellingShingle Trang Thu Doan
Setting the “right” goal: post M&A innovation performance and goal orientation
Business: Theory and Practice
mergers and acquisitions
innovation
R&D
goal orientation
acquisition experience
organizational learning
author_facet Trang Thu Doan
author_sort Trang Thu Doan
title Setting the “right” goal: post M&A innovation performance and goal orientation
title_short Setting the “right” goal: post M&A innovation performance and goal orientation
title_full Setting the “right” goal: post M&A innovation performance and goal orientation
title_fullStr Setting the “right” goal: post M&A innovation performance and goal orientation
title_full_unstemmed Setting the “right” goal: post M&A innovation performance and goal orientation
title_sort setting the “right” goal: post m&a innovation performance and goal orientation
publisher Vilnius Gediminas Technical University
series Business: Theory and Practice
issn 1648-0627
1822-4202
publishDate 2020-09-01
description Pharmaceutical firms spend billions of dollars to develop the next breakthrough drug and to maintain their market shares. We investigate how pharmaceutical firms use mergers and acquisitions to boost their innovation performance which has been found to result in better performance outcomes. Adding to the recent research on mergers and acquisitions, we found that firms that are explicit with their R&D goal orientation from the beginning of the acquisition journey are more successful in their innovation endeavours than firms with other goal orientation. Further, the firms’ prior acquisition experience appears to aid their innovation performance. However, we found that target size can affect the post-acquisition innovation performance but has diminishing returns as target size increases. Ultimately, our findings suggest that having an explicit R&D goal orientation is really important for a healthy innovation pipeline for pharmaceutical firms.
topic mergers and acquisitions
innovation
R&D
goal orientation
acquisition experience
organizational learning
url https://journals.vgtu.lt/index.php/BTP/article/view/12083
work_keys_str_mv AT trangthudoan settingtherightgoalpostmainnovationperformanceandgoalorientation
_version_ 1724573900824641536